aspirin and Peripheral Arterial Diseases studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Research Excerpts

Excerpt	Relevance	Reference
"In patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD) enrolled in The Cardiovascular Outcomes for People Using Anticoagulation Strategies trial, the effects of rivaroxaban 2."	9.51	Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial. ( Bhatt, DL; Bosch, J; Connolly, SJ; Eikelboom, JW; Fox, KAA; Hori, M; Liang, Y; Maggioni, A; Yusuf, S; Zhu, J, 2022)
"Clopidogrel is recommended in international guidelines to prevent arterial thrombotic events in patients with peripheral arterial disease (PAD)."	9.51	CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD). ( Adang, E; Coenen, M; Deneer, V; Donders, R; Kramers, C; Kranendonk, J; Reijnen, M; Vijver-Coppen, RV; Warlé, MC; Willems, LH; Zeebregts, CJ, 2022)
"5 mg twice daily rivaroxaban and aspirin in patients with polyvascular disease (coronary artery disease, peripheral arterial disease or both), the underlying mechanism of which is not clearly understood."	9.34	Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy. ( Bafford, R; Cummings, C; Gonze, M; Gurbel, P; Mackrell, P; Rout, A; Sukhi, A; Tantry, U; Ulloa, K, 2020)
"5 mg twice daily and aspirin 100 mg once daily compared with aspirin 100 mg once daily reduced major adverse cardiovascular events and mortality and increased bleeding."	9.30	Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. ( Berkowitz, SD; Bhatt, DL; Bosch, JJ; Cairns, JA; Connolly, SJ; Cook Bruns, N; Dagenais, GR; Diaz, R; Eikelboom, JW; Fox, KAA; Hart, RG; Leong, DP; Maggioni, AP; Muehlhofer, E; O'Donnell, M; Shestakovska, O; Tasto, C; Yusuf, S, 2019)
"In patients with chronic coronary artery disease or peripheral artery disease and a history of mild or moderate HF, combination rivaroxaban and aspirin compared with aspirin alone produces similar relative but larger absolute benefits than in those without HF."	9.30	Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. ( Avezum, A; Bhatt, DL; Bosch, J; Branch, KR; Cheng, RK; Connolly, SJ; Eikelboom, JW; Fox, KAA; Maggioni, AP; Probstfield, JL; Shestakovska, O; Yusuf, S, 2019)
"PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) randomized 21,162 patients with prior MI (1 to 3 years) to ticagrelor 90 mg twice daily, ticagrelor 60 mg twice daily, or placebo, all on a background of low-dose aspirin."	9.22	Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. ( Abola, MTB; Aylward, P; Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Corbalán, R; Dalby, A; Dellborg, M; Goodrich, E; Held, P; Jensen, EC; Kuder, J; López-Sendón, J; Nicolau, JC; Parkhomenko, A; Sabatine, MS; Špinar, J; Steg, PG; Storey, RF, 2016)
"This study aims to evaluate whether cilostazol plus aspirin is more efficacious than aspirin alone for preventing progression of atherosclerosis in patients with ischemic stroke or transient ischemic attack (TIA) who also have peripheral arterial disease."	9.20	The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): protocol of a randomized, double-blind, placebo-controlled multicenter trial. ( Chen, CH; Chen, ST; Chern, CM; Chiou, HY; Chiu, HC; Hsu, CY; Hu, HH; Jeng, JS; Lee, JT; Lien, LM; Lin, HJ; Lin, RT; Liu, CH; Ma, H; Po, HL; Sun, MC; Sun, MH; Sun, Y, 2015)
"Patients with PAD on ASA therapy at baseline were included from the ongoing Effect of Lipid Modification on Peripheral Arterial Disease after Endovascular Intervention Trial (ELIMIT), which is a randomized trial testing whether combination treatment with ezetimibe, niacin, and a statin will halt/regress atherosclerosis compared with statin monotherapy."	9.15	Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients. ( Ballantyne, CM; Dong, JF; Kimball, KT; Lumsden, AB; Morrisett, JD; Nambi, V; Saunders, J; Virani, SS, 2011)
" aspirin and placebo on platelet aggregation in peripheral arterial disease (PAD) patients."	9.14	Thromboxane Antagonism with terutroban in Peripheral Arterial Disease: the TAIPAD study. ( Bounameaux, H; Cairols, MA; Clement, DL; Coccheri, S; Fiessinger, JN; Fletcher, JP; Hoffmann, U; Turpie, AG, 2010)
"Vorapaxar is a novel antiplatelet agent that has demonstrated efficacy in reducing atherosclerotic events in patients with a history of MI or PAD without a history of stroke, transient ischemic attack, or ICH when taken in combination with aspirin and clopidogrel."	8.91	Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. ( Arif, SA; D'Souza, J; Gil, M; Gim, S, 2015)
" The currently available antiplatelet drugs used to prevent vascular events in patients with cardiovascular disease, including peripheral arterial disease (PAD), include aspirin and thienopyridines such as clopidogrel."	8.86	[The basis of platelets: platelets and atherothrombosis: an understanding of the lack of efficacy of aspirin in peripheral arterial disease (PAD) and diabetic patients]. ( Bal dit Sollier, C; Drouet, L; Henry, P, 2010)
"Dual pathway inhibition (DPI) with low-dose rivaroxaban and aspirin in patients with coronary artery disease (CAD) and/or peripheral artery disease (PAD) reduces the occurrence of cardiovascular (CV) events; however, the underlying mechanisms explaining these latter CV benefits are not clearly understood."	8.31	Dual Pathway Inhibition with Rivaroxaban and Aspirin Reduces Inflammatory Biomarkers in Atherosclerosis. ( Attena, E; Cotticelli, C; D'Alterio, G; D'Onofrio, A; Fabiani, D; Golino, P; Leonardi, S; Maione, B; Nigro, G; Rago, A; Russo, V; Sarpa, S, 2023)
" This study aims to compare the impact of aspirin (ASA) monotherapy, P2Y12 monotherapy, and DAPT on limb salvage (LS), amputation-free survival (AFS), and overall survival (OS) in patients undergoing lower extremity peripheral endovascular intervention (PVI) for chronic limb-threatening ischemia (CLTI)."	8.12	P2Y12 inhibitor monotherapy is associated with superior outcomes as compared with aspirin monotherapy in chronic limb-threatening ischemia. ( Dosluoglu, HH; Dryjski, ML; Fakhoury, E; Harris, LM; Khan, SZ; Montross, B; O'Brien-Irr, MS; Rivero, M, 2022)
" The COMPASS trial has shown that in patients with stable coronary artery disease (CAD) or peripheral artery disease (PAD), low-dose rivaroxaban (2."	8.12	[ANMCO Position paper: Evidence and practical indications for the use of low-dose rivaroxaban in stable coronary artery disease and peripheral artery disease]. ( Altamura, V; Bianco, M; Caldarola, P; Ceravolo, R; Cipriani, M; Colivicchi, F; De Luca, L; Di Fusco, SA; Francese, GM; Gabrielli, D; Gulizia, MM; Lucà, F; Nardi, F; Navazio, A; Oliva, F; Riccio, C; Rizzello, V; Scicchitano, P; Valente, S, 2022)
"This study aimed to investigate the cost-effectiveness of low-dose rivaroxaban plus aspirin versus aspirin alone for patients with stable cardiovascular diseases in the Taiwan setting."	8.02	Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases. ( Chang, WT; Chen, ZC; Chou, CC; Lee, MC; Liao, CT; Strong, C; Toh, HS; Wu, WS; Yu, T, 2021)
"The goal of this study is to establish the prevalence of high on-treatment platelet reactivity to aspirin (HPRA) and clopidogrel (HPRC) in patients with critical limb ischemia (CLI)."	7.88	Prevalence of high on-treatment (aspirin and clopidogrel) platelet reactivity in patients with critical limb ischemia. ( Al-Asady, N; Caro, J; Clavijo, LC; Dhillon, A; Matthews, RV; Rowe, V; Shavelle, DM; Tun, H, 2018)
"Our aims were to examine the prevalence and genetic predictors of aspirin and clopidogrel high on-treatment platelet reactivity (HoTPR), and associated adverse cardiovascular outcomes in patients with peripheral arterial disease (PAD)."	7.88	Aspirin and clopidogrel high on-treatment platelet reactivity and genetic predictors in peripheral arterial disease. ( Amsterdam, EA; Anderson, D; Armstrong, EJ; Chen, DC; Chiamvimonvat, N; Hua, A; Laird, JR; Li, CS; López, JE; Singapuri, A; Westin, GG; Yeo, KK, 2018)
"To evaluate long-term health benefits and risks of adding vorapaxar (VOR) to the standard care antiplatelet therapy (SC) of aspirin and/or clopidogrel, among a population with a recent myocardial infarction (MI) and/or peripheral artery disease (PAD)."	7.85	State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease. ( Chase, M; Davies, G; Du, M; Oguz, M, 2017)
"Clopidogrel or aspirin are indicated for patients with recent ischemic stroke (IS) or established peripheral artery disease (PAD)."	7.81	Clopidogrel versus aspirin in patients with recent ischemic stroke and established peripheral artery disease: an economic evaluation in a Chinese setting. ( Ben, H; Li, T; Liu, M; Wu, B; Xu, Z; Zhong, H, 2015)
"Clopidogrel, cilostazol, and aspirin were compared in terms of efficacy and safety for primary prevention of stroke in peripheral artery disease (PAD) patients."	7.79	Cilostazol for primary prevention of stroke in peripheral artery disease: a population-based longitudinal study in Taiwan. ( Chu, CY; Hsu, PC; Lai, WT; Lee, WH; Lin, TH; Sheu, SH; Su, HM; Voon, WC, 2013)
"The novel P2Y12 antagonist ticagrelor inhibits adenosine diphosphate (ADP)-induced platelet aggregation more potently than clopidogrel and reduces the incidence of myocardial infarction and total death in patients with an acute coronary syndrome (ACS)."	7.79	Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome. ( Erlinge, D; Larsson, J; Ohman, J; Salmi, H; Torngren, K, 2013)
"Patients with peripheral artery disease (PAD) following peripheral percutaneous transluminal angioplasty (PTA) with stent implantation are prone to stent thrombosis despite treatment with aspirin and clopidogrel."	7.79	Impaired responsiveness to clopidogrel and aspirin in patients with recurrent stent thrombosis following percutaneous intervention for peripheral artery disease. ( Frołow, M; Mazur, P; Niżankowski, R; Sadowski, J; Undas, A, 2013)
"Patients with lower extremity peripheral artery disease (PAD) are at increased risk of major adverse limb events (MALE)."	6.72	The efficacy and safety of direct oral anticoagulants plus aspirin in symptomatic lower extremity peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials. ( Costa, G; Gonçalves, L; Teixeira, R, 2021)
"However, both trials revealed excess diplopia (double vision) usually reversible after vorapaxar."	6.53	Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation. ( Can, M; Fortmann, SD; Hanley, DF; Kim, MH; Lordkipanidze, M; Marciniak, TA; Rao, SV; Serebruany, VL; Tanguay, JF, 2016)
"5 mg twice daily to aspirin or dual antiplatelet therapy significantly reduced this risk, with an increase in the bleeding risk, but had a favorable benefit risk for patients treated with bypass surgery, regardless of conduit type."	5.69	Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits. ( Anand, SS; Bauersachs, RM; Berkowitz, SD; Bonaca, MP; Capell, WH; Chung, J; Conte, MS; Debus, S; Dorigo, W; Govsyeyev, N; Gudz, I; Haskell, LP; Hess, CN; Jaeger, N; Krievins, D; Mills, J; Moll, F; Muehlhofer, E; Nehler, M; Norgren, L; Patel, MR; Piffaretti, G; Powell, R; Sillesen, H; Szalay, D; Szarek, M; Wohlauer, M, 2023)
"COMPASS trial patients with IAD <15 mmHg and IAD >15 mmHg were compared with respect to thirty-month incidence risk of: 1) composite of stroke, myocardial infarction, or cardiovascular death (MACE), 2) composite of acute limb-ischemia or vascular amputation (MALE), 3) composite of MACE or MALE, and 4) effects of treatment with the combination versus aspirin alone on these outcomes."	5.69	The predictive value of interarm systolic blood pressure differences in patients with vascular disease: Sub-analysis of the COMPASS trial. ( Aboyans, V; Anand, S; Bosch, J; Connolly, S; Eikelboom, J; Muehlhofer, E; Qadura, M; Syed, MH; Yusuf, S, 2023)
"5 mg twice daily plus aspirin, and to report their clinical outcomes and bleeding rates in clinical practice compared to the COMPASS randomized trial, which provided the basis for using DPI in this patient population."	5.51	Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry. ( Aboyans, V; Anand, SS; Bosch, J; Cowie, MR; Debus, ES; Fox, KAA; Gay, A; Patel, M; Vogtländer, K; Welsh, RC; Zeymer, U, 2022)
"In patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD) enrolled in The Cardiovascular Outcomes for People Using Anticoagulation Strategies trial, the effects of rivaroxaban 2."	5.51	Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial. ( Bhatt, DL; Bosch, J; Connolly, SJ; Eikelboom, JW; Fox, KAA; Hori, M; Liang, Y; Maggioni, A; Yusuf, S; Zhu, J, 2022)
"Clopidogrel is recommended in international guidelines to prevent arterial thrombotic events in patients with peripheral arterial disease (PAD)."	5.51	CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD). ( Adang, E; Coenen, M; Deneer, V; Donders, R; Kramers, C; Kranendonk, J; Reijnen, M; Vijver-Coppen, RV; Warlé, MC; Willems, LH; Zeebregts, CJ, 2022)
"The Clopidogrel and Acetylsalicylic Acid in Bypass Surgery for Peripheral Arterial Disease (CASPAR) trial is the only large, double-blind, placebo-controlled trial of dual antiplatelet therapy (DAPT) versus aspirin in patients with peripheral artery disease (PAD) after lower extremity revascularization (LER)."	5.51	Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a "CASPAR like" outcome from VOYAGER PAD. ( Anand, SS; Bauersachs, RM; Berkowitz, SD; Bonaca, MP; Debus, ES; Haskell, LP; Muehlhofer, E; Nehler, MR; Patel, MR; Szarek, M, 2022)
"Most parameters of thrombus formation under flow were similarly high for the patient and control groups."	5.42	Normal platelet activation profile in patients with peripheral arterial disease on aspirin. ( Baaten, CC; Clemetson, KJ; Cosemans, JM; de Laat, B; Heemskerk, JW; Kleinegris, MC; Roest, M; Ten Cate, H; van Geffen, JP; Verdoold, R, 2015)
" Furthermore, the current evidence seems to support that single-drug antiplatelet can be used as the basic treatment, and new antithrombotic strategies, such as ticagrelor only or aspirin combined with low-dose rivaroxaban are expected to further reduce the incidence of stroke for ICVD patients with PAD."	5.41	Early identification and treatment for peripheral arterial disease in patients with ischemic cerebrovascular disease. ( Li, LG; Ma, X, 2023)
"5 mg twice daily and aspirin 100 mg once daily compared with aspirin 100 mg once daily reduced major adverse cardiovascular events (MACE) in patients with chronic coronary artery disease or peripheral artery disease by 24% during a mean follow-up of 23 months."	5.41	Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. ( Anand, SS; Berkowitz, SD; Bosch, J; Connolly, SJ; Dagenais, GR; Eikelboom, JW; Fox, KA; Guzik, TJ; Keller, L; Liang, Y; Liu, L; Muehlhofer, E; O'Donnell, M; Shestakovska, O; Yusuf, S; Zhu, J, 2021)
"Incident composite of myocardial infarction, stroke or cardiovascular death was estimated per 100 person-years (py) during randomised treatment (n=18 278) and after study treatment discontinuation to non-study aspirin (n=14 068)."	5.41	Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. ( Aboyans, V; Berkowitz, SD; Bhatt, DL; Bosch, JJ; Connolly, SJ; Dagenais, GR; Dyal, L; Eikelboom, JW; Fox, KAA; Leong, DP; Muehlhofer, E; Probstfield, JL; Widimsky, P; Winkelmann, BR; Yusuf, S, 2021)
"5 mg rivaroxaban twice daily and 100 mg aspirin once daily compared with 100 mg aspirin once daily reduces major adverse cardiovascular (CV) events in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD)."	5.41	Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. ( Anand, SS; Avezum, A; Berkowitz, SD; Bhatt, DL; Bosch, J; Branch, KRH; Connolly, SJ; Dagenais, GR; Eikelboom, JW; Félix, C; Fox, KAA; Guzik, TJ; Hart, RG; Maggioni, AP; Muehlhofer, E; Sharma, M; Shestakovska, O; Yusuf, S, 2021)
"Atherosclerosis is a chronic inflammatory disease of the vessel wall."	5.36	Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. ( Conte, MS; Creager, MA; Ho, KJ; Kroemer, AH; Lancero, H; Owens, CD; Pande, R; Serhan, CN; Spite, M, 2010)
"5 mg twice daily rivaroxaban and aspirin in patients with polyvascular disease (coronary artery disease, peripheral arterial disease or both), the underlying mechanism of which is not clearly understood."	5.34	Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy. ( Bafford, R; Cummings, C; Gonze, M; Gurbel, P; Mackrell, P; Rout, A; Sukhi, A; Tantry, U; Ulloa, K, 2020)
"5 mg twice daily plus aspirin was associated with a significantly lower incidence of the composite outcome of acute limb ischemia, major amputation for vascular causes, myocardial infarction, ischemic stroke, or death from cardiovascular causes than aspirin alone."	5.34	Rivaroxaban in Peripheral Artery Disease after Revascularization. ( Anand, SS; Bauersachs, RM; Berkowitz, SD; Bonaca, MP; Brodmann, M; Capell, WH; Debus, ES; Diao, L; Diaz, R; Fanelli, F; Gudz, I; Haskell, LP; Hess, CN; Hiatt, WR; Jaeger, N; Kittelson, JM; Krievins, DK; Mátyás, L; Muehlhofer, E; Nehler, MR; Pap, AF; Patel, MR, 2020)
" There were no statistically significant differences between rivaroxaban and aspirin prophylaxis for recurrent ischemic stroke in patients with non-stenotic intracranial atherosclerosis and/or systemic atherosclerosis."	5.34	Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy. ( Amarenco, P; Ameriso, SF; Bereczki, D; Berkowitz, SD; Connolly, SJ; Ferrari, J; Firstenfeld, A; Hart, RG; Kasner, SE; Lang, W; Lavados, P; Mikulik, R; Mundl, H; Ntaios, G; Pearce, LA; Perera, KS; Povedano, GP; Uchiyama, S; Yoon, BW, 2020)
"5 mg twice daily and aspirin 100 mg once daily compared with aspirin 100 mg once daily reduced major adverse cardiovascular events and mortality and increased bleeding."	5.30	Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. ( Berkowitz, SD; Bhatt, DL; Bosch, JJ; Cairns, JA; Connolly, SJ; Cook Bruns, N; Dagenais, GR; Diaz, R; Eikelboom, JW; Fox, KAA; Hart, RG; Leong, DP; Maggioni, AP; Muehlhofer, E; O'Donnell, M; Shestakovska, O; Tasto, C; Yusuf, S, 2019)
"Strokes were significantly reduced by the combination of rivaroxaban plus aspirin in comparison with aspirin in the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies)."	5.30	Stroke Outcomes in the COMPASS Trial. ( Aboyans, V; Alings, M; Berkowitz, SD; Bhatt, DL; Bosch, J; Bruns, NC; Catanese, L; Connolly, SJ; Eikelboom, JW; Fox, K; Ha, JW; Hart, RG; Keltai, K; Maggioni, A; Ng, KKH; O'Donnell, M; Sharma, M; Shestakovska, O; Tonkin, A; Varigos, J; Yusuf, S, 2019)
" In patients with prior coronary artery disease or peripheral arterial disease the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial revealed that compared with acetylsalicylic acid alone, dual pathway inhibition with low-dose rivaroxaban (2."	5.30	Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease. ( Coppens, M; Eikelboom, JWA; Weitz, JI, 2019)
"5 mg bd plus aspirin), versus aspirin alone, are preserved in patients with moderate renal dysfunction without evidence of an excess hazard of bleeding."	5.30	Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial. ( Connolly, SJ; Eikelboom, JW; Fox, KAA; Metsarinne, KP; Shestakovska, O; Yusuf, S, 2019)
"In patients with chronic coronary artery disease or peripheral artery disease and a history of mild or moderate HF, combination rivaroxaban and aspirin compared with aspirin alone produces similar relative but larger absolute benefits than in those without HF."	5.30	Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. ( Avezum, A; Bhatt, DL; Bosch, J; Branch, KR; Cheng, RK; Connolly, SJ; Eikelboom, JW; Fox, KAA; Maggioni, AP; Probstfield, JL; Shestakovska, O; Yusuf, S, 2019)
" The combination of rivaroxaban plus aspirin compared with aspirin alone reduced the composite endpoint of cardiovascular death, myocardial infarction, or stroke (126 [5%] of 2492 vs 174 [7%] of 2504; hazard ratio [HR] 0·72, 95% CI 0·57-0·90, p=0·0047), and major adverse limb events including major amputation (32 [1%] vs 60 [2%]; HR 0·54 95% CI 0·35-0·82, p=0·0037)."	5.27	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. ( Aboyans, V; Alings, M; Anand, SS; Avezum, AA; Bangdiwala, SI; Bhatt, DL; Bosch, J; Branch, K; Chen, E; Commerford, PJ; Connolly, SJ; Diaz, R; Eikelboom, JW; Fox, KAA; Hart, RG; Kakkar, AK; Keltai, K; Leong, DP; Lewis, BS; Lopez-Jaramillo, P; Maggioni, AP; Misselwitz, F; O'Donnell, M; Pogosova, N; Ryden, L; Störk, S; Vanassche, T; Varigos, JD; Vinereanu, D; Widimsky, P; Yusuf, S; Zhu, J, 2018)
"These results suggest that patients who have undergone EVT have similar risks for major and life-threatening bleeding events with edoxaban and aspirin compared with clopidogrel and aspirin."	5.27	Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial. ( Adams, G; Ansel, G; Baumgartner, I; Grosso, M; Jaff, M; Lin, M; Mercur, MF; Minar, E; Moll, F; Nwachuku, C; Rundback, J; Tangelder, M; Zeller, T, 2018)
"The DAPT (Dual Antiplatelet Therapy) study randomized 11,648 patients free from ischemic and bleeding events 12 months after coronary stenting to continued thienopyridine plus aspirin therapy for an additional 18 months versus aspirin therapy alone."	5.24	Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. ( Apruzzese, PK; Cutlip, DE; Kereiakes, DJ; Massaro, JM; Mauri, L; Secemsky, EA; Steg, PG; Yeh, RW, 2017)
"To perform a systematic literature review and indirect treatment comparison (ITC) to identify, summarize and quantify randomized controlled trial (RCT) evidence evaluating combination anticoagulant or P2Y12 inhibitor with low-dose aspirin versus low-dose aspirin alone for the prevention of atherothrombotic events in patients with stable coronary artery disease (CAD) and/or peripheral artery disease (PAD)."	5.22	Combination anticoagulant or P2Y12 inhibitor with low-dose aspirin versus low-dose aspirin alone in patients at risk or with documented coronary and/or peripheral artery disease. ( Baker, WL; Bookhart, B; Coleman, CI; Kharat, AA, 2022)
" Clinical equipoise also persists around questions such as the utility of dual antiplatelet therapy in conjunction with rivaroxaban after high-risk endovascular interventions and the optimal therapy for patients experiencing acute limb ischemia."	5.22	Antithrombotic Therapy in Peripheral Artery Disease: Risk Stratification and Clinical Decision Making. ( Anand, SS; Chan, N; Kaplovitch, E; McClure, GR, 2022)
"High-quality evidence from trials directly comparing single antiplatelet therapies in symptomatic peripheral arterial disease (PAD) to dual antiplatelet therapies or acetylsalicylic acid (ASA) plus low-dose rivaroxaban is lacking."	5.22	Antithrombotic Therapy for Symptomatic Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis. ( de Borst, GJ; Hannink, G; Kramers, K; Maas, DPMSM; Mees, BME; Reijnen, MMPJ; Riksen, NP; Ten Cate, H; van der Vijver-Coppen, RJ; Warlé, MC; Willems, LH; Zeebregts, CJ, 2022)
"PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) randomized 21,162 patients with prior MI (1 to 3 years) to ticagrelor 90 mg twice daily, ticagrelor 60 mg twice daily, or placebo, all on a background of low-dose aspirin."	5.22	Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. ( Abola, MTB; Aylward, P; Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Corbalán, R; Dalby, A; Dellborg, M; Goodrich, E; Held, P; Jensen, EC; Kuder, J; López-Sendón, J; Nicolau, JC; Parkhomenko, A; Sabatine, MS; Špinar, J; Steg, PG; Storey, RF, 2016)
"This study aims to evaluate whether cilostazol plus aspirin is more efficacious than aspirin alone for preventing progression of atherosclerosis in patients with ischemic stroke or transient ischemic attack (TIA) who also have peripheral arterial disease."	5.20	The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): protocol of a randomized, double-blind, placebo-controlled multicenter trial. ( Chen, CH; Chen, ST; Chern, CM; Chiou, HY; Chiu, HC; Hsu, CY; Hu, HH; Jeng, JS; Lee, JT; Lien, LM; Lin, HJ; Lin, RT; Liu, CH; Ma, H; Po, HL; Sun, MC; Sun, MH; Sun, Y, 2015)
"Patients with PAD on ASA therapy at baseline were included from the ongoing Effect of Lipid Modification on Peripheral Arterial Disease after Endovascular Intervention Trial (ELIMIT), which is a randomized trial testing whether combination treatment with ezetimibe, niacin, and a statin will halt/regress atherosclerosis compared with statin monotherapy."	5.15	Variability and persistence of aspirin response in lower extremity peripheral arterial disease patients. ( Ballantyne, CM; Dong, JF; Kimball, KT; Lumsden, AB; Morrisett, JD; Nambi, V; Saunders, J; Virani, SS, 2011)
"The Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) trial was a prospective, randomized, open-label trial conducted throughout Japan that enrolled 2,539 type 2 diabetic patients without a history of atherosclerotic diseases."	5.15	Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. ( Akai, Y; Doi, N; Jinnouchi, H; Morimoto, T; Nakayama, M; Ogawa, H; Okada, S; Saito, Y; Soejima, H; Sugiyama, S; Uemura, S; Waki, M, 2011)
" aspirin and placebo on platelet aggregation in peripheral arterial disease (PAD) patients."	5.14	Thromboxane Antagonism with terutroban in Peripheral Arterial Disease: the TAIPAD study. ( Bounameaux, H; Cairols, MA; Clement, DL; Coccheri, S; Fiessinger, JN; Fletcher, JP; Hoffmann, U; Turpie, AG, 2010)
" Dual-antiplatelet therapy is the standard of care for secondary prevention in patients with acute coronary syndrome (ACS), whereas single antiplatelet therapy, generally with aspirin, is the standard of care for secondary prevention in stable patients with coronary artery disease (CAD), peripheral artery disease (PAD), or cerebrovascular disease."	5.05	Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence. ( Angiolillo, DJ; Geisler, T; Heitmeier, S; Weitz, JI, 2020)
"The COMPASS trial demonstrated that in patients with stable atherosclerotic disease, very low-dose rivaroxaban, a direct factor Xa inhibitor, when combined with aspirin, reduced the rate of recurrent ischemic events, at the cost of increased bleeding."	5.05	Aspirin and low-dose rivaroxaban - the dual pathway concept in patients with stable atherosclerotic disease: a comprehensive review. ( Eisen, A; Parascandolo, E, 2020)
"Aspirin decreases the risk of recurrent thrombotic events in patients with coronary artery disease or peripheral artery disease but the risk of recurrent events remains high."	5.01	How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland? ( Eikelboom, JW; Guzik, TJ; Kruger, PC, 2019)
" Patients with mesenteric ischaemia caused by atherosclerosis should be evaluated concerning platelet antiaggregation with low dose aspirin or clopidogrel, and those with cardioembolic disease should be recommended anticoagulant treatment with either warfarin or one of the direct oral anticoagulants (DOAC; apixaban, dabigatran, edoxaban, or rivaroxaban)."	4.95	Pharmacological secondary prevention in patients with mesenterial artery atherosclerosis and arterial embolism. ( Gottsäter, A, 2017)
"Vorapaxar is a novel antiplatelet agent that has demonstrated efficacy in reducing atherosclerotic events in patients with a history of MI or PAD without a history of stroke, transient ischemic attack, or ICH when taken in combination with aspirin and clopidogrel."	4.91	Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. ( Arif, SA; D'Souza, J; Gil, M; Gim, S, 2015)
"The use of aspirin is considered the "gold standard" for the decrease of major adverse cardiovascular events in patients with atherosclerosis, including peripheral arterial disease (PAD), whereas a dual-antiplatelet regimen with aspirin and clopidogrel is usually indicated for such patients after angioplasty and stent deployment."	4.90	High on-treatment platelet reactivity in peripheral endovascular procedures. ( Hatzidakis, A; Kassimis, G; Krokidis, M; Spiliopoulos, S, 2014)
" Of 2 treatment trials meeting inclusion criteria, 1 large trial (n = 3350) showed that low-dose aspirin did not prevent CVD events in persons with a screen-detected low ABI but may have increased the risk for major bleeding events."	4.89	The ankle-brachial index for peripheral artery disease screening and cardiovascular disease prediction among asymptomatic adults: a systematic evidence review for the U.S. Preventive Services Task Force. ( Johnson, ES; Lin, JS; Olson, CM; Whitlock, EP, 2013)
"To assess the clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole (MRD) alone or with aspirin (ASA) compared with ASA (and each other where appropriate) in the prevention of occlusive vascular events in patients with a history of MI, ischaemic stroke/TIA or established peripheral arterial disease."	4.87	Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. ( Bagust, A; Blundell, M; Boland, A; Dickson, R; Dundar, Y; Fisher, M; Greenhalgh, J; Martin Saborido, C; Oyee, J; Proudlove, C, 2011)
" The currently available antiplatelet drugs used to prevent vascular events in patients with cardiovascular disease, including peripheral arterial disease (PAD), include aspirin and thienopyridines such as clopidogrel."	4.86	[The basis of platelets: platelets and atherothrombosis: an understanding of the lack of efficacy of aspirin in peripheral arterial disease (PAD) and diabetic patients]. ( Bal dit Sollier, C; Drouet, L; Henry, P, 2010)
"The innovative pharmacological combination of low-dose rivaroxaban plus aspirin provides clinicians with an ideal opportunity to intensify the medical treatment of patients with coronary artery disease (CAD) and comorbid peripheral artery disease (PAD)."	4.31	Cost-effectiveness analysis of screening for peripheral artery disease in patients with coronary artery disease in China: A Markov model. ( Qiu, Y; Wang, Y; Xing, Y; Yang, L; Yuan, Z, 2023)
"Dual pathway inhibition (DPI) with low-dose rivaroxaban and aspirin in patients with coronary artery disease (CAD) and/or peripheral artery disease (PAD) reduces the occurrence of cardiovascular (CV) events; however, the underlying mechanisms explaining these latter CV benefits are not clearly understood."	4.31	Dual Pathway Inhibition with Rivaroxaban and Aspirin Reduces Inflammatory Biomarkers in Atherosclerosis. ( Attena, E; Cotticelli, C; D'Alterio, G; D'Onofrio, A; Fabiani, D; Golino, P; Leonardi, S; Maione, B; Nigro, G; Rago, A; Russo, V; Sarpa, S, 2023)
"In unselected patients undergoing revascularization for peripheral arterial disease, the majority presents with characteristics that, at present, preclude prescription of rivaroxaban in addition to aspirin."	4.12	Prevalence of VOYAGER PAD trial exclusion criteria in unselected patients undergoing lower limb revascularization. ( Grassl, KJ; Klocker, J; Moll, CW; Moll, MA; Neururer, SB; Westreicher, W; Wipper, SH; Zwerger, D, 2022)
" This study aims to compare the impact of aspirin (ASA) monotherapy, P2Y12 monotherapy, and DAPT on limb salvage (LS), amputation-free survival (AFS), and overall survival (OS) in patients undergoing lower extremity peripheral endovascular intervention (PVI) for chronic limb-threatening ischemia (CLTI)."	4.12	P2Y12 inhibitor monotherapy is associated with superior outcomes as compared with aspirin monotherapy in chronic limb-threatening ischemia. ( Dosluoglu, HH; Dryjski, ML; Fakhoury, E; Harris, LM; Khan, SZ; Montross, B; O'Brien-Irr, MS; Rivero, M, 2022)
" The COMPASS trial has shown that in patients with stable coronary artery disease (CAD) or peripheral artery disease (PAD), low-dose rivaroxaban (2."	4.12	[ANMCO Position paper: Evidence and practical indications for the use of low-dose rivaroxaban in stable coronary artery disease and peripheral artery disease]. ( Altamura, V; Bianco, M; Caldarola, P; Ceravolo, R; Cipriani, M; Colivicchi, F; De Luca, L; Di Fusco, SA; Francese, GM; Gabrielli, D; Gulizia, MM; Lucà, F; Nardi, F; Navazio, A; Oliva, F; Riccio, C; Rizzello, V; Scicchitano, P; Valente, S, 2022)
"Background The COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial decreased major adverse cardiovascular events with very low-dose rivaroxaban and aspirin in patients with coronary artery disease and peripheral artery disease."	4.12	Eligibility and Implementation of Rivaroxaban for Secondary Prevention of Atherothrombosis in Clinical Practice-Insights From the CANHEART Study. ( Abdel-Qadir, H; Chu, A; Farkouh, ME; Ferreira-Legere, LE; Goodman, SG; Ko, DT; Porter, J; Sheth, MS; Tam, DY; Udell, JA; Yu, B, 2022)
"This study aimed to investigate the cost-effectiveness of low-dose rivaroxaban plus aspirin versus aspirin alone for patients with stable cardiovascular diseases in the Taiwan setting."	4.02	Cost-effectiveness analysis of rivaroxaban plus aspirin versus aspirin alone in secondary prevention among patients with chronic cardiovascular diseases. ( Chang, WT; Chen, ZC; Chou, CC; Lee, MC; Liao, CT; Strong, C; Toh, HS; Wu, WS; Yu, T, 2021)
"5 mg twice daily) plus aspirin (100 mg once daily) with aspirin alone in patients with coronary artery disease (CAD) or peripheral artery disease (PAD) and related subgroups."	4.02	Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy. ( Cortesi, PA; Di Laura, D; Ferrara, P; Maggioni, AP; Mantovani, LG, 2021)
"5 mg rivaroxaban twice daily plus 100 mg aspirin once daily may be a promising alternative to 100 mg aspirin antiplatelet therapy for the prevention of cardiovascular events in patients with coronary artery disease and/or peripheral arterial disease."	3.96	Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study. ( Joore, M; Petersohn, S; Pouwels, X; Ramaekers, B; Ten Cate-Hoek, A, 2020)
"A total of 176 patients taking antiplatelet medications aspirin and/or clopidogrel with peripheral artery disease (PAD) and/or carotid stenosis (CS) were included in the study."	3.96	Perioperative changes of response to antiplatelet medication in vascular surgery patients. ( Breuer-Kaiser, A; Düsterwald, JO; Hummel, T; Meves, SH; Mühlberger, D; Mumme, A; Neubauer, H, 2020)
"Circulating MPA are a robust marker of platelet activity and monocyte inflammation, unaffected by low-dose aspirin, and are significantly elevated in subjects with CVD, particularly those with PAD."	3.91	Circulating monocyte-platelet aggregates are a robust marker of platelet activity in cardiovascular disease. ( Allen, N; Barrett, TJ; Berger, JS; Guo, Y; Hochman, JS; Nardi, M; Ramkhelawon, B; Rockman, CB, 2019)
"In the COMPASS trial, combined aspirin and rivaroxaban treatment reduced ischaemic events in patients with stable coronary artery disease (CAD) or peripheral artery disease (PAD)."	3.91	External applicability of the COMPASS trial: the Western Denmark Heart Registry. ( Eikelboom, JW; Kristensen, SD; Maeng, M; Olesen, KKW; Thim, T; Würtz, M, 2019)
"The aims of the present study were to describe the proportion of patients eligible for the COMPASS trial within the Reduction of Atherothrombosis for Continued Health (REACH) registry, the reasons for ineligibility, and to put in perspective the characteristics and outcomes of trial-eligible patients from the REACH registry compared with those of patients enrolled in the reference aspirin arm of the COMPASS trial."	3.88	External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. ( Aboyans, V; Abtan, J; Anand, S; Bhatt, DL; Bosch, J; Branch, KR; Connolly, SJ; Darmon, A; Ducrocq, G; Dyal, L; Eagle, KA; Eikelboom, JW; Elbez, Y; Fox, KAA; Keltai, K; Probstfield, J; Sorbets, E; Steg, PG; Yusuf, S, 2018)
"The goal of this study is to establish the prevalence of high on-treatment platelet reactivity to aspirin (HPRA) and clopidogrel (HPRC) in patients with critical limb ischemia (CLI)."	3.88	Prevalence of high on-treatment (aspirin and clopidogrel) platelet reactivity in patients with critical limb ischemia. ( Al-Asady, N; Caro, J; Clavijo, LC; Dhillon, A; Matthews, RV; Rowe, V; Shavelle, DM; Tun, H, 2018)
"Our aims were to examine the prevalence and genetic predictors of aspirin and clopidogrel high on-treatment platelet reactivity (HoTPR), and associated adverse cardiovascular outcomes in patients with peripheral arterial disease (PAD)."	3.88	Aspirin and clopidogrel high on-treatment platelet reactivity and genetic predictors in peripheral arterial disease. ( Amsterdam, EA; Anderson, D; Armstrong, EJ; Chen, DC; Chiamvimonvat, N; Hua, A; Laird, JR; Li, CS; López, JE; Singapuri, A; Westin, GG; Yeo, KK, 2018)
"To evaluate long-term health benefits and risks of adding vorapaxar (VOR) to the standard care antiplatelet therapy (SC) of aspirin and/or clopidogrel, among a population with a recent myocardial infarction (MI) and/or peripheral artery disease (PAD)."	3.85	State transition model: vorapaxar added to standard antiplatelet therapy to prevent thrombosis post myocardial infarction or peripheral artery disease. ( Chase, M; Davies, G; Du, M; Oguz, M, 2017)
"Restenosis and stent thrombosis after endovascular intervention in patients with peripheral arterial disease (PAD) can potentially be tackled by more intensive antiplatelet therapy, such as dual antiplatelet therapy (DAPT) consisting of aspirin and P2Y12 inhibitor."	3.83	High On-Treatment Platelet Reactivity in Peripheral Arterial Disease: A Pilot Study to Find the Optimal Test and Cut Off Values. ( Asselbergs, FW; de Borst, GJ; den Ruijter, HM; Leunissen, TC; Moll, FL; Peeters Weem, SM; Urbanus, RT, 2016)
"Current guidelines recommend antithrombotic therapy with either aspirin or clopidogrel for all patients with peripheral arterial disease (PAD)."	3.81	Adverse cardiovascular outcomes in relation to suboptimal antithrombotic therapy use in patients undergoing peripheral artery disease angioplasty: lost opportunities? ( Allon, IR; Apostolakis, S; Bodansky, DM; Lip, GY, 2015)
"This study was conducted to determine whether there is additive benefit of dual-antiplatelet therapy (DAPT) with aspirin (acetylsalicylic acid [ASA]) and clopidogrel compared with ASA monotherapy among patients with symptomatic peripheral arterial disease."	3.81	Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease. ( Amsterdam, EA; Anderson, DR; Armstrong, EJ; Bang, H; Freischlag, JA; Laird, JR; Singh, GD; Yeo, KK, 2015)
"Clopidogrel or aspirin are indicated for patients with recent ischemic stroke (IS) or established peripheral artery disease (PAD)."	3.81	Clopidogrel versus aspirin in patients with recent ischemic stroke and established peripheral artery disease: an economic evaluation in a Chinese setting. ( Ben, H; Li, T; Liu, M; Wu, B; Xu, Z; Zhong, H, 2015)
"Current guidelines recommend that patients with peripheral arterial disease (PAD) cease smoking and be treated with aspirin, statin medications, and angiotensin-converting enzyme (ACE) inhibitors."	3.80	Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. ( Amsterdam, EA; Anderson, D; Armstrong, EJ; Bang, H; Chen, DC; Laird, JR; McCoach, CE; Singh, S; Westin, GG; Yeo, KK, 2014)
" Patients with critical limb ischemia following stent thrombosis were included if dual antiplatelet therapy consisting of 100 mg aspirin and 75 mg clopidogrel per day had been administered over three months prior to enrollment."	3.80	Response to dual antiplatelet therapy in patients with peripheral artery occlusive disease suffering from critical limb ischemia. ( Baecker, C; Baro, D; Meybohm, P; Mutlak, H; Schmitz-Rixen, T; Wand, S; Weber, CF; Zacharowski, K, 2014)
"Clopidogrel, cilostazol, and aspirin were compared in terms of efficacy and safety for primary prevention of stroke in peripheral artery disease (PAD) patients."	3.79	Cilostazol for primary prevention of stroke in peripheral artery disease: a population-based longitudinal study in Taiwan. ( Chu, CY; Hsu, PC; Lai, WT; Lee, WH; Lin, TH; Sheu, SH; Su, HM; Voon, WC, 2013)
"The novel P2Y12 antagonist ticagrelor inhibits adenosine diphosphate (ADP)-induced platelet aggregation more potently than clopidogrel and reduces the incidence of myocardial infarction and total death in patients with an acute coronary syndrome (ACS)."	3.79	Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome. ( Erlinge, D; Larsson, J; Ohman, J; Salmi, H; Torngren, K, 2013)
"Patients with peripheral artery disease (PAD) following peripheral percutaneous transluminal angioplasty (PTA) with stent implantation are prone to stent thrombosis despite treatment with aspirin and clopidogrel."	3.79	Impaired responsiveness to clopidogrel and aspirin in patients with recurrent stent thrombosis following percutaneous intervention for peripheral artery disease. ( Frołow, M; Mazur, P; Niżankowski, R; Sadowski, J; Undas, A, 2013)
"Vorapaxar is a novel antiplatelet therapy that inhibits thrombin-mediated platelet aggregation to prevent recurrence of ischemic events."	3.01	Protease-Activated Receptor Antagonist for Reducing Cardiovascular Events - A Review on Vorapaxar. ( Aedma, SK; Combs, WG; Gupta, R; Kluck, B; Lin, M; Mehta, A; Patel, NC; Ranchal, P; Shah, R; Singh, S; Vyas, AV, 2023)
"In the VOYAGER PAD trial, rivaroxaban plus aspirin reduced the risk of adverse cardiovascular and limb events with an early benefit for acute limb ischemia regardless of clopidogrel use."	2.94	Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety. ( Anand, SS; Bauersachs, R; Berkowitz, SD; Bonaca, MP; Brackin, T; Brasil, D; Capell, WH; Debus, ES; Haskell, L; Hess, CN; Hiatt, WR; Jaeger, N; Madaric, J; Muehlhofer, E; Nehler, MR; Pap, AF; Patel, MR; Sillesen, H; Szalay, D, 2020)
"We examined new cancers diagnosed in relation to gastrointestinal or genitourinary bleeding among patients enrolled in the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies) and determined the hazard of new cancer diagnosis after bleeding at these sites."	2.90	Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. ( Aboyans, V; Alings, M; Anand, SS; Avezum, A; Berkowitz, SD; Bhatt, DL; Bosch, J; Connolly, SJ; Cook-Bruns, N; Eikelboom, JW; Felix, C; Fox, KAA; Hart, RG; Maggioni, AP; Moayyedi, P; O'Donnell, M; Rydén, L; Shestakovska, O; Verhamme, P; Widimsky, P; Yusuf, S; Zhu, J, 2019)
" These drugs are well tolerated in the short term, but long-term treatment was associated with adverse events in observational studies."	2.90	Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. ( Alings, M; Anand, SS; Avezum, A; Bhatt, DL; Bosch, J; Branch, KRH; Bruns, NC; Commerford, PJ; Connolly, SJ; Dagenais, GR; Dans, AL; Diaz, R; Dyal, L; Eikelboom, JW; Ertl, G; Felix, C; Fox, KAA; Guzik, TJ; Hart, RG; Hori, M; Kakkar, AK; Keltai, M; Kim, JH; Lanas, F; Leong, D; Lewis, BS; Liang, Y; Lonn, EM; Lopez-Jaramillo, P; Maggioni, AP; Metsarinne, KP; Moayyedi, P; Muehlhofer, E; O'Donnell, M; Parkhomenko, AN; Piegas, LS; Pogosova, N; Probstfield, J; Ryden, L; Shestakovska, O; Steg, PG; Störk, S; Tonkin, AM; Torp-Pedersen, C; Verhamme, PB; Vinereanu, D; Widimsky, P; Yusoff, K; Yusuf, S; Zhu, J, 2019)
"Ticagrelor is a P2Y12 receptor antagonist with evidence of cardiovascular event reduction in patients with acute coronary syndromes and those with a previous myocardial infarction."	2.87	Ticagrelor and the Prevention of Microvascular Complications in Diabetes Patients with Lower Extremity Arterial Disease; Rationale and Design of the Hema-Kinesis Trial. ( Chen, Q; Cho, DJ; Lee, ML; Najera, SD; Rosenson, RS, 2018)
" Secondary outcomes include target lesion revascularization, major bleeding, ipsilateral major amputation, all-cause mortality, and all adverse events that take place in those six months."	2.84	SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial. ( Ahn, S; Cho, MJ; Cho, S; Ha, J; Kim, SY; Lee, J; Min, SI; Min, SK, 2017)
"Cilostazol has been reported to reduce intimal hyperplasia and subsequent repeat revascularization."	2.79	Efficacy of two different self-expanding nitinol stents for atherosclerotic femoropopliteal arterial disease (SENS-FP trial): study protocol for a randomized controlled trial. ( Bae, JH; Baek, JY; Bong, JM; Cho, JH; Cho, YH; Choi, CU; Choi, HJ; Choi, SH; Choi, WG; Chung, WY; Her, SH; Kang, WY; Kim, EJ; Kim, JH; Kim, KC; Kim, MW; Kim, SM; Kim, WH; Kim, YH; Kim, YJ; Lee, SJ; Oh, DJ; Park, MW; Park, SH; Rha, SW; Seo, JB; Soh, JW; Suh, J, 2014)
"Secondary end points were the restenosis rate on duplex ultrasound, the rate of major adverse cardiac events, and target lesion event-free survival."	2.78	Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. ( Hamasaki, T; Hirano, K; Iida, O; Inoue, N; Isshiki, T; Kawasaki, D; Miyamoto, A; Miyashita, Y; Nakamura, M; Nanto, S; Shinozaki, N; Shintani, Y; Soga, Y; Suzuki, K; Tsuchiya, T; Urasawa, K; Yokoi, H; Yokoi, Y; Zen, K, 2013)
" Efficacy (major adverse cardiovascular events, acute or chronic limb ischaemia, vascular amputation, peripheral revascularisation) and safety (all-cause mortality and overall bleeding) outcomes were evaluated via Bayesian network meta-analyses."	2.72	Efficacy and Safety of Antiplatelet Therapies in Symptomatic Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis. ( Cimminiello, C; De Carlo, M; Di Minno, G; Fazeli, MS; Sayre, T; Siliman, G, 2021)
"Patients with lower extremity peripheral artery disease (PAD) are at increased risk of major adverse limb events (MALE)."	2.72	The efficacy and safety of direct oral anticoagulants plus aspirin in symptomatic lower extremity peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials. ( Costa, G; Gonçalves, L; Teixeira, R, 2021)
"Patients with peripheral artery disease are at high-risk for cardiovascular events."	2.58	[Anti-Thrombotic Treatment of Patients with Peripheral Artery Disease (PAD)]. ( Espinola-Klein, C, 2018)
"Peripheral artery disease is a common manifestation of systemic atherosclerosis which strongly correlates to cardiovascular morbidity and mortality."	2.58	Novel Oral Anticoagulants in Peripheral Artery Disease: Current Evidence. ( Argyriou, C; Georgakarakos, EI; Georgiadis, GS; Koutsoumpelis, A; Tasopoulou, KM, 2018)
"However, both trials revealed excess diplopia (double vision) usually reversible after vorapaxar."	2.53	Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation. ( Can, M; Fortmann, SD; Hanley, DF; Kim, MH; Lordkipanidze, M; Marciniak, TA; Rao, SV; Serebruany, VL; Tanguay, JF, 2016)
"In the peripheral arteries, a thrombus superimposed on atherosclerosis contributes to the progression of peripheral artery disease (PAD), producing intermittent claudication (IC), ischemic necrosis, and, potentially, loss of the limb."	2.50	Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. ( Cafaro, G; de Gaetano, G; Di Minno, A; Di Minno, G; Lupoli, R; Petitto, M; Spadarella, G; Tremoli, E, 2014)
"After the procedure, deep vein thrombosis (DVT) was a commonly diagnosed complication (3."	1.91	Incidence of venous thromboembolism in patients with peripheral arterial disease after endovascular intervention. ( Agala, C; Caruso, DM; Duchesneau, E; Farber, M; Kindell, DG; Marston, WA; Marulanda, K; McGinigle, KL, 2023)
"Peripheral artery disease affects 1."	1.51	Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective. ( Ademi, Z; Hird, TR; Liew, D; Owen, AJ; Reid, CM; Si, S; Tonkin, A; Zomer, E, 2019)
"Most parameters of thrombus formation under flow were similarly high for the patient and control groups."	1.42	Normal platelet activation profile in patients with peripheral arterial disease on aspirin. ( Baaten, CC; Clemetson, KJ; Cosemans, JM; de Laat, B; Heemskerk, JW; Kleinegris, MC; Roest, M; Ten Cate, H; van Geffen, JP; Verdoold, R, 2015)
"Atorvastatin 80 mg was found to be independent predictor of survival, and major amputation was found to be independent predictor of mortality."	1.39	Long-term results of plaque excision combined with aggressive pharmacotherapy in high-risk patients with advanced peripheral artery disease (SAVE a LEG registry). ( Buszman, PE; Buszman, PP; Kiesz, RS; Konkolewska, MD; Martin, JL; Radvany, MG; Szymanski, R; Wiernek, BK; Wiernek, SL, 2013)
"Peripheral arterial disease is a manifestation of systemic atherosclerosis and is predictive of future cardiovascular events."	1.38	The quality and impact of risk factor control in patients with stable claudication presenting for peripheral vascular interventions. ( Ardati, AK; Aronow, HD; Bove, PG; Grossman, PM; Gurm, HS; Kaufman, SR; Nypaver, TJ, 2012)
"Atherosclerosis is a chronic inflammatory disease of the vessel wall."	1.36	Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. ( Conte, MS; Creager, MA; Ho, KJ; Kroemer, AH; Lancero, H; Owens, CD; Pande, R; Serhan, CN; Spite, M, 2010)

Research

Studies (222)

Authors

Clinical Trials (38)

Trial Overview

Trial Outcomes

All-cause Mortality

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	127 (57.21)	24.3611
2020's	95 (42.79)	2.80

Authors	Studies
Anand, SS	26
Hiatt, W	1
Dyal, L	6
Bauersachs, R	4
Berkowitz, SD	21
Branch, KRH	7
Debus, S	4
Fox, KAA	18
Liang, Y	5
Muehlhofer, E	20
Nehler, M	3
Haskell, LP	10
Patel, M	2
Szarek, M	8
Yusuf, S	21
Eikelboom, J	4
Bonaca, MP	16
Zhang, J	1
Vallabhaneni, SR	2
Lip, GYH	2
Basili, S	2
Romiti, GF	1
Cangemi, R	1
Corica, B	1
Wu, O	1
Hawkins, N	1
Bowrin, K	2
Wojciechowski, P	1
Clay, E	1
Huelsebeck, M	1
Kotalczyk, A	1
Coleman, CI	1
Kharat, AA	1
Bookhart, B	1
Baker, WL	1
Gupta, R	3
Lin, M	2
Mehta, A	2
Aedma, SK	1
Shah, R	1
Ranchal, P	1
Vyas, AV	1
Singh, S	2
Kluck, B	1
Combs, WG	1
Patel, NC	1
Li, W	1
Zhang, H	1
Xiang, Q	1
Cui, Y	1
Kawashima, H	1
Serruys, PW	1
Wang, R	1
Lunardi, M	1
Onuma, Y	1
Moll, MA	1
Zwerger, D	1
Grassl, KJ	1
Westreicher, W	1
Neururer, SB	1
Moll, CW	1
Wipper, SH	1
Klocker, J	1
Søgaard, M	1
Nielsen, PB	1
Skjøth, F	1
Larsen, TB	1
Eldrup, N	1
Golledge, J	1
Marcaccio, CL	1
Patel, PB	1
Wang, S	1
Rastogi, V	1
Moreira, CC	1
Siracuse, JJ	1
Schermerhorn, ML	2
Stangenberg, L	1
Bauersachs, RM	10
Nehler, MR	9
Debus, ES	10
Patel, MR	13
Capell, WH	9
Hess, CN	9
Hsia, J	4
Leeper, NJ	1
Brasil, D	2
Mátyás, L	3
Diaz, R	6
Brodmann, M	4
McClure, GR	2
Kaplovitch, E	3
Chan, N	1
Eikelboom, JW	21
Bosch, J	17
Connolly, SJ	18
Tyrwitt, J	1
Neumann, C	1
Tasto, C	2
Bangdiwala, SI	4
Alings, M	7
Dagenais, GR	7
Leong, DP	4
Lonn, EM	2
Avezum, A	8
Piegas, LS	2
Widimsky, P	7
Parkhomenko, AN	2
Bhatt, DL	20
Probstfield, JL	4
Lopez-Jaramillo, P	3
Rydén, L	5
Pogosova, N	4
Keltai, K	5
Keltai, M	2
Ertl, G	3
Stoerk, S	1
Dans, AL	2
Lanas, F	2
Zhu, J	6
Torp-Pedersen, C	2
Maggioni, AP	10
Commerford, PJ	3
Guzik, TJ	5
Vanassche, T	3
Verhamme, P	6
O'Donnell, M	7
Tonkin, AM	2
Varigos, JD	2
Vinereanu, D	3
Felix, C	4
Kim, JH	3
Ibrahim, KS	1
Lewis, BS	3
Metsarinne, KP	3
Aboyans, V	16
Steg, PG	7
Hori, M	3
Kakkar, A	1
Lamy, A	3
Sharma, M	3
Zeymer, U	2
Cowie, MR	3
Welsh, RC	1
Gay, A	2
Vogtländer, K	2
Majumdar, M	3
Imran, R	1
Yi, J	1
Baumgartner, I	3
Capell, W	1
Khan, SZ	1
O'Brien-Irr, MS	1
Fakhoury, E	1
Montross, B	1
Rivero, M	1
Dosluoglu, HH	1
Harris, LM	1
Dryjski, ML	1
Shestakovska, O	11
Beckman, JA	2
Piazza, G	1
Henkin, S	1
Bura-Rivière, A	2
Lawall, H	1
Roztocil, K	1
Maggioni, A	2
Goto, S	2
Kranendonk, J	1
Willems, LH	2
Vijver-Coppen, RV	1
Coenen, M	1
Adang, E	1
Donders, R	1
Zeebregts, CJ	2
Deneer, V	1
Reijnen, M	1
Kramers, C	1
Warlé, MC	2
Maas, DPMSM	1
Kramers, K	1
Reijnen, MMPJ	1
Riksen, NP	1
Ten Cate, H	3
van der Vijver-Coppen, RJ	1
de Borst, GJ	3
Mees, BME	1
Hannink, G	1
Tong, W	1
Yuan, F	1
Connolly, S	2
Lonn, E	1
Wang, WJ	1
Probstfield, J	3
Störk, S	3
Durand-Zaleski, I	1
Waller, D	1
Poyant, J	1
McElroy, I	1
Lella, S	1
Feldman, ZM	1
Levine, E	1
Kim, Y	1
Nuzzolo, K	1
Kirshkaln, A	1
DeCarlo, C	1
Dua, A	2
Adik-Pathak, L	1
Shirodkar, S	1
Gupta, A	1
Kindell, DG	1
Marulanda, K	1
Caruso, DM	1
Duchesneau, E	1
Agala, C	1
Farber, M	1
Marston, WA	1
McGinigle, KL	1
De Carlo, M	3
Schlager, O	1
Mazzolai, L	2
Espinola-Klein, C	4
Staub, D	1
Sillesen, H	4
Venermo, M	1
Belch, J	1
Ferrari, M	1
De Caterina, R	2
Xing, Y	1
Qiu, Y	1
Yang, L	1
Yuan, Z	1
Wang, Y	2
Hayashi, N	1
Matsuyama, Y	1
Fujiwara, T	1
Govsyeyev, N	3
Conte, MS	4
Chung, J	2
Dorigo, W	2
Gudz, I	3
Krievins, D	3
Mills, J	3
Moll, F	3
Norgren, L	2
Piffaretti, G	3
Powell, R	2
Szalay, D	3
Wohlauer, M	2
Jaeger, N	5
Di Fusco, SA	2
Rizzello, V	2
Scicchitano, P	2
Lucà, F	2
Altamura, V	2
Bianco, M	2
De Luca, L	3
Valente, S	2
Riccio, C	2
Caldarola, P	2
Cipriani, M	2
Francese, GM	2
Navazio, A	2
Nardi, F	2
Ceravolo, R	2
Gulizia, MM	2
Gabrielli, D	2
Oliva, F	2
Colivicchi, F	2
Sheth, MS	2
Yu, B	2
Chu, A	2
Porter, J	2
Tam, DY	2
Ferreira-Legere, LE	2
Goodman, SG	2
Farkouh, ME	2
Ko, DT	2
Abdel-Qadir, H	2
Udell, JA	2
Carlin, S	1
de Vries, TAC	2
Budaj, A	1
Russo, V	1
Fabiani, D	1
Leonardi, S	1
Attena, E	1
D'Alterio, G	1
Cotticelli, C	1
Rago, A	1
Sarpa, S	1
Maione, B	1
D'Onofrio, A	1
Golino, P	1
Nigro, G	1
Yi, Q	1
Han, A	1
Lee, T	1
Lee, J	2
Song, SW	1
Lee, SS	1
Jung, IM	1
Kang, JM	1
Gwon, JG	1
Yun, WS	1
Cho, YP	1
Ko, H	1
Park, YJ	1
Min, SK	2
Li, LG	1
Ma, X	1
Qadura, M	1
Syed, MH	1
Anand, S	2
Weissler, EH	1
Stebbins, A	1
Wruck, L	1
Muñoz, D	1
Gupta, K	1
Girotra, S	1
Whittle, J	1
Benziger, CP	1
Polonsky, TS	1
Bradley, SM	1
Hammill, BG	1
Merritt, JG	1
Zemon, DN	1
Hernandez, AF	1
Jones, WS	3
Matheny, H	1
O'Banion, LA	1
Spaccarotella, C	1
Simonetti, F	1
Piccolo, R	2
Esposito, G	1
Suarez Ferreira, SP	1
Hall, RP	1
Goudot, G	1
Jessula, S	1
Bellomo, T	1
Lee, I	1
Kukreja, N	1
Parmar, G	1
Boada, AE	1
Kokkinidis, DG	1
Schizas, D	1
Pargaonkar, S	1
Karamanis, D	1
Mylonas, KS	1
Hasemaki, N	1
Palaiodimos, L	1
Varrias, D	1
Tzavellas, G	1
Siasos, G	1
Klonaris, C	1
Kharawala, A	1
Chlorogiannis, DD	1
Georgopoulos, S	1
Bakoyiannis, C	1
Cleland, JGF	1
Pellicori, P	1
Narula, S	1
Bhagirath, VC	1
Cook-Bruns, N	2
Hart, RG	7
Moayyedi, P	2
Bosch, JJ	2
Cairns, JA	1
Cook Bruns, N	1
Bode, C	1
Olivier, CB	1
Duerschmied, D	1
Hardung, D	1
Behne, A	1
Langhoff, R	1
Fox, KA	2
Levy, P	1
Mealing, S	1
Millier, A	1
Mernagh, P	1
Cristeau, O	1
Briere, JB	1
Lin, Z	1
Zhang, L	1
Yang, X	1
Liu, L	2
Xuan, J	1
Monje, D	1
Lawatscheck, R	1
Tantry, U	2
Cummings, C	1
Mackrell, P	1
Gonze, M	1
Ulloa, K	1
Bafford, R	1
Rout, A	1
Sukhi, A	1
Gurbel, P	1
Fanelli, F	3
Diao, L	1
Pap, AF	2
Kittelson, JM	2
Krievins, DK	2
Hiatt, WR	10
Petersohn, S	1
Pouwels, X	1
Ramaekers, B	1
Ten Cate-Hoek, A	1
Joore, M	1
Keller, L	1
Chiarito, M	1
Sanz-Sánchez, J	1
Cannata, F	1
Cao, D	1
Sturla, M	1
Panico, C	1
Godino, C	1
Regazzoli, D	1
Reimers, B	1
Condorelli, G	1
Ferrante, G	2
Stefanini, GG	1
Weitz, JI	4
Angiolillo, DJ	1
Geisler, T	1
Heitmeier, S	1
Barbarash, OL	1
Kashtalap, VV	1
Marone, EM	1
Rinaldi, LF	1
Chierico, S	1
Marazzi, G	1
Palmieri, P	1
Lovotti, M	1
Klersy, C	1
Ameriso, SF	1
Amarenco, P	1
Pearce, LA	1
Perera, KS	1
Ntaios, G	1
Lang, W	1
Bereczki, D	1
Uchiyama, S	1
Kasner, SE	1
Yoon, BW	1
Lavados, P	1
Firstenfeld, A	1
Mikulik, R	1
Povedano, GP	1
Ferrari, J	1
Mundl, H	1
Colak, B	1
Orhan, A	1
Ece, I	1
Yormaz, S	1
Yilmaz, H	1
Sahin, M	1
Biagioni, RB	1
Lopes, RD	1
Agati, LB	1
Sacilotto, R	1
Wolosker, N	1
Sobreira, ML	1
de Freitas Soares, BL	1
Joviliano, EE	1
Bernardi, WH	1
Junior, VC	1
Caffaro, RA	1
Fioranelli, A	1
Van Bellen, B	1
Casella, IB	1
Fidelis, RJR	1
Flumignan, RLG	1
Comerota, AJ	1
Ramacciotti, E	1
Parascandolo, E	1
Eisen, A	1
Sperling, LS	1
Wells, BJ	1
Darmon, A	3
Elbez, Y	2
Abtan, J	2
Mas, JL	1
Cacoub, P	1
Montalescot, G	1
Billaut-Laden, I	1
Ducrocq, G	3
Singh, N	1
Ding, L	1
Magee, GA	1
Shavelle, DM	2
Kashyap, VS	3
Garg, PK	1
Lanthier, L	1
Huard, G	1
Plourde, ME	1
Cauchon, M	1
Di Minno, G	2
Sayre, T	1
Fazeli, MS	1
Siliman, G	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424]	Phase 3	27,395 participants (Actual)	Interventional	2013-02-28	Completed
An International, Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Thrombotic Vascular Events in Patients With Symptomatic Peripheral Artery Disease Un[NCT02504216]	Phase 3	6,564 participants (Actual)	Interventional	2015-08-18	Completed
HELicobacter Pylori Screening to Prevent Gastrointestinal Bleeding in Patients With Acute Myocardial Infarction Trial Based on the SWEDEHEART Registry (HELP-SWEDEHEART)[NCT05024864]		22,000 participants (Anticipated)	Interventional	2021-11-17	Recruiting
Xarelto + Acetylsalicylic Acid: Treatment Patterns and Outcomes in Patients With Atherosclerosis. A Non-interventional Study[NCT03746275]		5,798 participants (Actual)	Observational	2018-11-13	Completed
Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy[NCT04059679]	Phase 4	30 participants (Anticipated)	Interventional	2020-01-30	Recruiting
Safety and Efficacy of Century Clot-Guided Prophylactic Rivaroxaban Therapy for Post ST-Segment Elevation Myocardial Infarction Complicating Left Ventricular Thrombus Compared With Conventional Antiplatelet Therapy[NCT06013020]	Phase 4	374 participants (Anticipated)	Interventional	2023-08-28	Recruiting
Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in Subjects With Symptomatic Peripheral Artery Disease (PAD) Undergoing Infrapopliteal Endovascular Peripheral Revascularization Procedures in Patients With Critical Limb[NCT04229264]	Phase 3	200 participants (Anticipated)	Interventional	2020-01-09	Recruiting
SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study : a Randomized Controlled Trial[NCT02959606]	Phase 4	272 participants (Anticipated)	Interventional	2016-12-31	Recruiting
Influence of Rivaroxaban 2.5 mg Two Times a Day for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic Peripheral Arterial Disease (PAD) - a Randomised Controlled Trial[NCT04305028]		100 participants (Anticipated)	Observational	2021-03-10	Not yet recruiting
DUAL Pathway Inhibition (Low-dose Rivaroxaban and Aspirin) as Compared to Aspirin Only to Improve Endothelial Function in Peripheral Artery Disease.[NCT04218656]	Phase 4	159 participants (Actual)	Interventional	2020-06-08	Completed
Registry Dedicated to Assess the Risk of Ischemic and Hemorrhagic Complications of Long-term Antithrombotic Therapy in Patients With Chronic Coronary Syndromes[NCT04347200]		2,000 participants (Anticipated)	Observational [Patient Registry]	2015-01-15	Recruiting
A Randomized, Open-Label, Parallel-Group, Multi-Center Study Of Adding Edoxaban Or Clopidogrel To Aspirin To Maintain Patency In Subjects With Peripheral Arterial Disease Following Femoropopliteal Endovascular Intervention[NCT01802775]	Phase 2	203 participants (Actual)	Interventional	2013-02-06	Completed
A Phase II Multicentre, Randomised, Double-Blind, Controlled, Parallel-Group Study to Evaluate the Walking Time Effect of Long-Term Ticagrelor in Comparison to Long-Term Aspirin Administration in Ambulatory Patients With Peripheral Artery Disease Undergoi[NCT02227368]	Phase 2	40 participants (Actual)	Interventional	2014-10-20	Terminated
Health Program for prEvention of cardiovascuLar disEases Based on a Risk screeNing Strategy With Ankle-brachial Index.[NCT05884840]		54,000 participants (Anticipated)	Interventional	2023-11-20	Recruiting
Antiplatelet Resistance Research in Patients With Peripheral Arterial Revascularization[NCT03953547]		88 participants (Actual)	Observational	2018-01-01	Completed
OCT Evaluation of Early Vascular Repair in Patients With Non ST Elevation Acute Coronary Syndrome (NSTE-ACS)[NCT04375319]		60 participants (Anticipated)	Interventional	2019-10-28	Recruiting
Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting[NCT04694248]		172 participants (Anticipated)	Interventional	2021-11-03	Recruiting
The Efficacy and Safety of Proton Pump Inhibitor ( in Patients With Moderate Bleeding Risk and Coronary Artery Disease Undergoing Percutaneous Coronary: A Randomised, Open ,Compared With Control[NCT05820048]	Phase 4	300 participants (Anticipated)	Interventional	2023-05-01	Not yet recruiting
Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function and Other Circulating Biomarkers in Humans[NCT02587260]	Phase 4	54 participants (Actual)	Interventional	2015-12-17	Completed
Evaluation of Antiplatelet Therapy in Lower Limb Endovascular Treatment[NCT00912756]	Phase 4	200 participants (Anticipated)	Interventional	2009-03-31	Recruiting
Follow-up Management of Peripheral Arterial Intervention With Clopidogrel MIRROR-Study[NCT00163267]	Phase 2/Phase 3	80 participants (Actual)	Interventional	2005-09-30	Completed
Arterial Imaging of Inflammation and Resolution After Endovascular Surgery[NCT03590769]	Phase 1	9 participants (Actual)	Interventional	2017-06-01	Completed
Efficacy of Self-Expanding Nitinol S.M.A.R.T-CONTROL Stent Versus Complete SE Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease : Prospective, Multicenter, Randomized, Controlled Trial (SENS-FP Trial)[NCT01570803]		0 participants (Actual)	Interventional	2013-01-31	Withdrawn (stopped due to Study could not be initiated due to lack of research funding from the sponsors.)
The Effect Of Acadesine On Clinically Significant Adverse Cardiovascular and Cerebrovascular Events In High-Risk Subjects Undergoing Coronary Artery Bypass Graft (CABG) Surgery Using Cardiopulmonary Bypass (Protocol No. P05633): RED-CABG Trial (Reduction [NCT00872001]	Phase 3	3,080 participants (Actual)	Interventional	2009-04-30	Terminated
A Multi-center, Randomized, Double-blind and Placebo-controlled Clinical Research of 2200 Cases in Improving Curative Effect of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM[NCT02334969]	Phase 4	2,200 participants (Actual)	Interventional	2016-04-30	Completed
Allogeneic Mesenchymal Stromal Cells for Angiogenesis and Neovascularization in No-option Ischemic Limbs; A Double-blind, Randomized, Placebo-controlled Trial[NCT03042572]	Phase 2/Phase 3	60 participants (Anticipated)	Interventional	2018-12-31	Not yet recruiting
Intra-arterial Infusion of Autologous Bone Marrow Mononuclear Cells in Patients With Chronic Critical Limb Ischemia: a Randomized, Placebo-controlled Clinical Trial[NCT00371371]	Phase 1/Phase 2	160 participants (Actual)	Interventional	2006-09-30	Completed
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myoca[NCT01225562]	Phase 3	21,379 participants (Actual)	Interventional	2010-10-31	Completed
Influence of Platelet Reactivity in Peripheral Arterial Disease Patients Undergoing Percutaneous Angioplasty on Mid-term Outcomes[NCT04165629]		450 participants (Anticipated)	Observational	2020-01-01	Recruiting
PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY[NCT00611286]	Phase 4	1,700 participants (Anticipated)	Interventional	2006-12-31	Completed
Aspirin Resistance in Obstructive Sleep Apnea Patients (ARISA Trial)[NCT03930875]		63 participants (Actual)	Observational	2017-12-12	Completed
Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents[NCT00638794]		8,575 participants (Actual)	Observational	2008-01-31	Completed
THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease[NCT02719665]		30 participants (Actual)	Interventional	2016-03-31	Completed
Omega EVAR: Use of Fish Oil to Reduce Inflammation During Endovascular Abdominal Aortic Repair.[NCT03208920]		2 participants (Actual)	Interventional	2016-12-31	Completed
"Effect of Lipid Modification on Peripheral Arterial Disease After Endovascular Intervention (The ELIMIT Trial)"[NCT00687076]	Phase 4	102 participants (Actual)	Interventional	2004-04-30	Completed
Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial[NCT00110448]	Phase 4	2,539 participants (Actual)	Interventional	2002-12-31	Completed
Assessment of Exercise Capacity, Physical Activity, Pulmonary Function, Peripheric and Respiratory Muscle Strength, Respiratory Muscle Endurance in Patient With Peripheral Artery Disease[NCT03458754]		35 participants (Actual)	Observational	2018-01-01	Completed
Effects of Prolonged Dual Antiplatelet Therapy With Clopidogrel Plus Acetylsalicylic Acid (ASA) After Percutaneous Lower Extremity Revascularization in Patients With Peripheral Arterial Disease[NCT02798913]	Phase 3	300 participants (Anticipated)	Interventional	2016-01-31	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

All-cause Mortality in LTOLE Part

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg	313
Rivaroxaban 5mg + Aspirin Placebo	366
Rivaroxaban Placebo + Aspirin 100mg	378

Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.

The First Occurrence of MI, Ischemic Stroke, ALI, or Cardiovascular (CV) Death

Intervention	Participants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg	282

Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

The First Occurrence of Myocardial Infarction (MI), Ischemic Stroke, Acute Limb Ischemia (ALI), or Coronary Heart Disease (CHD) Death

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg	389
Rivaroxaban 5mg + Aspirin Placebo	453
Rivaroxaban Placebo + Aspirin 100mg	516

Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg	329
Rivaroxaban 5mg + Aspirin Placebo	397
Rivaroxaban Placebo + Aspirin 100mg	450

Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

The First Occurrence of the Composite Primary Efficacy Outcome, Myocardial Infarction (MI), Stroke, or Cardiovascular (CV) Death in LTOLE Part

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg	379
Rivaroxaban 5mg + Aspirin Placebo	448
Rivaroxaban Placebo + Aspirin 100mg	496

Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.

The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria

Intervention	Participants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg	353

"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.

The First Occurrence of the Primary Safety Outcome Major Bleeding Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria in LTOLE Part

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5mg + Aspirin 100mg	288
Rivaroxaban 5mg + Aspirin Placebo	255
Rivaroxaban Placebo + Aspirin 100mg	170

"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.

Number of Mortality (All-cause)

Intervention	Participants (Count of Participants)
LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg	138

(NCT02504216)
Timeframe: For each participant, the first occurrence of the outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1188.48 days

Number of Participants With an Unplanned Index Limb Revascularization for Recurrent Limb Ischemia (Subsequent Index Leg Revascularization That Was Not Planned or Considered as Part of the Initial Treatment Plan at the Time of Randomization)

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od	321
Rivaroxaban Placebo Bid + Aspirin 100 mg od	297

Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1062.48 days.

Number of Participants With Composite of MI, All-cause Stroke, Cardiovascular (CV) Death, Acute Limb Ischemia (ALI), and Major Amputation of a Vascular Etiology

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od	584
Rivaroxaban Placebo Bid + Aspirin 100 mg od	655

Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the composite efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1108.29 days

Number of Participants With Composite of MI, Ischemic Stroke, All-cause Mortality (ACM), ALI, and Major Amputation of a Vascular Etiology

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od	514
Rivaroxaban Placebo Bid + Aspirin 100 mg od	588

Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the composite efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1085.13 days

Number of Participants With Composite of MI, Ischemic Stroke, Coronary Heart Disease (CHD) Death, ALI, and Major Amputation of a Vascular Etiology

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od	614
Rivaroxaban Placebo Bid + Aspirin 100 mg od	679

Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the composite efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1108.79 days.

Number of Participants With Hospitalization for a Coronary or Peripheral Cause (Either Lower Limb) of a Thrombotic Nature

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od	433
Rivaroxaban Placebo Bid + Aspirin 100 mg od	528

Number of Participants With Venous Thromboembolic (VTE) Events

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od	262
Rivaroxaban Placebo Bid + Aspirin 100 mg od	356

Venous thromboembolic events were reported by investigator only. (NCT02504216)
Timeframe: For each participant, the first occurrence of the outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1187.65 days

Primary Efficacy Outcome: Number of Participants With Composite of Myocardial Infarction (MI), Ischemic Stroke, Cardiovascular Death, Acute Limb Ischemia (ALI) and Major Amputation Due to a Vascular Etiology

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od	25
Rivaroxaban Placebo Bid + Aspirin 100 mg od	41

Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean time in follow-up survival time until ECOD that date was 1109.76 days.

Primary Safety Outcome: Number of Participants With TIMI (Thrombolysis in Myocardial Infarction) Major Bleeding

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od	508
Rivaroxaban Placebo Bid + Aspirin 100 mg od	584

Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the primary safety outcome after randomization up until 2 days after permanent stop of study drug (rivaroxaban or rivaroxaban placebo).

Secondary Safety Outcome: Number of Participants With BARC (Bleeding Academic Research Consortium) Type 3b and Above Bleeding Events

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od	62
Rivaroxaban Placebo Bid + Aspirin 100 mg od	44

Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered (NCT02504216)
Timeframe: For each participant, the first occurrence of the type 3b and above bleeding events according to the BARC classification after randomization up until 2 days after permanent stop of study drug (rivaroxaban or rivaroxaban placebo)

Secondary Safety Outcome: Number of Participants With ISTH (International Society on Thrombosis and Haemostasis) Major Bleeding

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od	93
Rivaroxaban Placebo Bid + Aspirin 100 mg od	73

Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered. (NCT02504216)
Timeframe: For each participant, the first occurrence of the major bleeding events according to the ISTH classification after randomization up until 2 days after permanent stop of study drug (rivaroxaban or rivaroxaban placebo).

Number of Adjudicated Major Adverse Cardiovascular Events During the Overall Study Period

Intervention	Participants (Count of Participants)
Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od	140
Rivaroxaban Placebo Bid + Aspirin 100 mg od	100

Number of Adjudicated Major Adverse Cardiovascular Events (MACE) which is a composite of non-fatal myocardial infarction (MI), non-fatal stroke and cardiovascular death (NCT01802775)
Timeframe: within 6 months

Number of Participants With Amputations

Intervention	Participants (Count of Participants)
Clopidogrel	1
Edoxaban	3

Number of participants with amputations within 6 months (NCT01802775)
Timeframe: within 6 months

Percentage of Participants With First Re-stenosis / Re-occlusion

Intervention	Participants (Count of Participants)
Clopidogrel	3
Edoxaban	1

Percentage of participants with re-stenosis/re-occlusion during treatment within 6 months - only the first occurrence of re-stenosis / re-occlusion was counted for each participant (NCT01802775)
Timeframe: within 6 months

Safety Assessments

Intervention	percentage of participants (Number)
Clopidogrel	34.7
Edoxaban	30.9

"Number of participants with serious adverse events (SAEs) within 6 months~Note: Based on changes to the database structure, clinically significant changes in physical or laboratory parameters are recorded as adverse events (AEs). Details of non-serious adverse events are reported at the 5% reporting threshold in the AE module, as is all-cause mortality." (NCT01802775)
Timeframe: within 6 months

Percentage of Participants With Clinically Relevant Bleeding During Treatment

Intervention	Participants (Count of Participants)
Clopidogrel	30
Edoxaban	31

Percentage of participants with clinically relevant bleeding, defined as major bleeding or clinical relevant non-major bleeding, in the on-treatment period based on International Society of Thrombosis and Haemostasis (ISTH) (NCT01802775)
Timeframe: at 3 months

Percentage of Participants With Major, Clinically Relevant Non-major (CRNM), and Minor Bleeding During Treatment

Intervention	percentage of participants (Number)
	Including Access Site Bleeding (IASB)	Excluding Access Site Bleed (EASB)
Clopidogrel	8	6
Edoxaban	11	6

The percentage of participants with major, clinically relevant non-major, and minor bleeding occurring during treatment, within 3 months (NCT01802775)
Timeframe: within 3 months

Change From Baseline in Log Transformed Claudication Onset Time (COT) at Week 26 or Early Termination (ET)

Change From Baseline in Log Transformed Peak Walking Time (PWT) at Week 26 or Early Termination (ET)

Incidence of All-cause Death, Non-fatal Stroke, and Need for Mechanical Support for Severe Left Ventricular Dysfunction (SLVD) (Intent-to-Treat Population)

Intervention	percentage of participants (Number)
	IASB : Major Bleeding	IASB: CRNM Bleeding	IASB: Minor Bleeding	EASB : Major Bleeding	EASB : CRNM Bleeding	EASB : Minor Bleeding
Clopidogrel	5	4	20.8	4	3	17.8
Edoxaban	1	10	20	1	5	19

Intervention	log(Second) (Mean)
Ticagrelor	0.6
Aspirin	0.5

Intervention	log(Second) (Mean)
Ticagrelor	0.0
Aspirin	0.1

Incidence of all-cause death, non-fatal stroke, or need for mechanical support for SLVD (any component and composite) through post-operative Day 28 during and following CABG and administration of acadesine or placebo. Components defined as follows: All-cause death: Death from any cause, Non-fatal Stoke: occurrence of a stoke that was confirmed and adjudicated by Clinical Endpoints Committee that did not result in death, and Mechanical Support for SLVD: New use of any mechanical support for ≥1 hour for treatment of low cardiac output. (NCT00872001)
Timeframe: Up to Post-Operative Day 28

Incidence of Cardiovascular Death, Non-fatal Stroke, and Need for Mechanical Support for SLVD (Intent-to-Treat Population)

Intervention	Percentage of Participants (Number)
	Composite of All Events	All-Cause Death	Non-Fatal Stroke	Need for Mechanical Support for SLVD
Acadesine	4.9	1.9	1.7	2.2
Placebo	4.9	1.7	1.7	2.3

Incidence of cardiovascular death, non-fatal stroke, and need for mechanical support for SLVD (any component and composite) through post-operative Day 28 during and following CABG and administration of acadesine or placebo. Components defined as follows: Cardiovascular death: Death due to cardiovascular causes, Non-fatal Stroke: occurrence of a stroke that was confirmed and adjudicated by Clinical Endpoints Committee that did not result in death, and Mechanical Support for SLVD: New use of any mechanical support for ≥1 hour for treatment of low cardiac output. (NCT00872001)
Timeframe: Up to Post-Operative Day 28

Kaplan-Meier Estimate of the Percentage of Patients Who Died From Any Cause Within 3 Years From Randomization

Intervention	Percentage of Participants (Number)
	Composite of All Events	Cardiovascular Death	Non-Fatal Stroke	Need for Mechanical Support for SLVD
Acadesine	4.8	1.7	1.7	2.2
Placebo (Normal Saline)	4.7	1.6	1.7	2.3

Participants with death from any cause. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent or the last time point the particapant was known to be alive. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who died from any cause within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months

Kaplan-Meier Estimate of the Percentage of Patients Who Experienced a TIMI Major Bleeding Within 3 Years From First Dose of Study Drug Units: Percentage of Patients

Intervention	Percentage of Patients (Number)
Ticagrelor 90 mg	5.1
Ticagrelor 60 mg	4.7
Placebo	5.2

A Thrombolysis in Myocardial Infarction (TIMI) study group major bleeding is defined as any fatal bleeding (leading directly to death within 7 days), any intrcranial bleeding or any clinically overt signs of haemorrhage associated with a drop in Haemoglobin of >= 5g/dL. Events were adjudicated by a clinical events committee. Censoring ocurrs at 7 days following last dose of study drug. The Kaplan-Meier estimate reports the percentage of patients who experienced a TIMI Major bleeding within 3 years from first dose of study drug (NCT01225562)
Timeframe: First dosing up to 48 months

Kaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death) Within 3 Years From Randomization

Intervention	Percentage of Patients (Number)
Ticagrelor 90 mg	2.6
Ticagrelor 60 mg	2.3
Placebo	1.1

Participants with CV death. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months

Kaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death), Myocardial Infarction (MI) or Stroke Within 3 Years From Randomization

Intervention	Percentage of Patients (Number)
Ticagrelor 90 mg	2.9
Ticagrelor 60 mg	2.9
Placebo	3.4

Participants with CV death, MI or Stroke. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death, MI or stroke within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months

Change in Total Cholesterol (mg/dl) From Baseline to Month 12

Intervention	Percentage of Patients (Number)
Ticagrelor 90 mg	7.8
Ticagrelor 60 mg	7.8
Placebo	9.0

Lipids: Total cholesterol (mg/dl); Lipid Data at 12-Months (change from baseline) [mg/dl]. (NCT00687076)
Timeframe: Measured at baseline and 12 months

Effect of Intensive Lipid Modification Medication Therapy on Progression of Atherosclerosis and Restenosis of Femoral Arteries Measured Using High Resolution Magnetic Resonance Imaging (MRI) to Examine the Femoral Artery for Progression of Atherosclerosis

Intervention	mg/dl (Median)
Triple Therapy	-30.0
Mono Therapy	-7.5

"The primary outcome variable was the change in superficial femoral artery (SFA) wall volume over 24-months, as determined by MRI. The 24-month changes in SFA lumen and SFA total vessel volumes were also analyzed.~Analysis details: A total of 102 patients were randomized. 87 patients completed baseline MRI. Between randomization and the baseline visit, 1 patient withdrew from the study, 8 patients opted out from baseline imaging, and 6 additional patients declined blood collection at baseline. The multilevel models (primary endpoint) used all available imaging data (n=91), including patients who only completed baseline imaging (n=20) or completed at least 2 imaging visits other than baseline (n=4)." (NCT00687076)
Timeframe: Measured at baseline and 24 Months

Article	Year
Efficacy and Safety of Rivaroxaban Compared with Other Therapies Used in Patients with Peripheral Artery Disease Undergoing Peripheral Revascularization: A Systematic Literature Review and Network Meta-Analysis. Cardiovascular therapeutics, 2021, Volume: 2021 Topics: Adult; Aspirin; Humans; Network Meta-Analysis; Peripheral Arterial Disease; Platelet Aggregation Inh	2021
Review new concepts in pharmacotherapy for peripheral arterial disease. Current opinion in cardiology, 2021, 11-01, Volume: 36, Issue:6 Topics: Aspirin; Drug Therapy, Combination; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibi	2021
Combination anticoagulant or P2Y12 inhibitor with low-dose aspirin versus low-dose aspirin alone in patients at risk or with documented coronary and/or peripheral artery disease. Current medical research and opinion, 2022, Volume: 38, Issue:1 Topics: Adult; Anticoagulants; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibi	2022
Protease-Activated Receptor Antagonist for Reducing Cardiovascular Events - A Review on Vorapaxar. Current problems in cardiology, 2023, Volume: 48, Issue:3 Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Myocardial Infarction; Peripheral Arterial Di	2023
Update on the pathophysiology and medical treatment of peripheral artery disease. Nature reviews. Cardiology, 2022, Volume: 19, Issue:7 Topics: Aspirin; Humans; Pain; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Quality of Life	2022
Antithrombotic Therapy in Peripheral Artery Disease: Risk Stratification and Clinical Decision Making. The Canadian journal of cardiology, 2022, Volume: 38, Issue:5 Topics: Aspirin; Canada; Clinical Decision-Making; Drug Therapy, Combination; Fibrinolytic Agents; Hemorrhag	2022
A comprehensive review on antithrombotic therapy for peripheral artery disease. Seminars in vascular surgery, 2022, Volume: 35, Issue:2 Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Humans; Peripheral Arterial Disease; Platelet Aggregat	2022
Antithrombotic Therapy for Symptomatic Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis. Drugs, 2022, Volume: 82, Issue:12 Topics: Aspirin; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Humans; Network Meta-Analysis; Peripheral Art	2022
Early identification and treatment for peripheral arterial disease in patients with ischemic cerebrovascular disease. European journal of medical research, 2023, Feb-23, Volume: 28, Issue:1 Topics: Aspirin; Atherosclerosis; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Stro	2023
Who may benefit from low-dose rivaroxaban plus aspirin? Practical implications for outpatients with cardiovascular disease. Polish archives of internal medicine, 2023, 10-26, Volume: 133, Issue:10 Topics: Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Ischemia;	2023
Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios. Current cardiology reports, 2019, 08-30, Volume: 21, Issue:10 Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Factor Xa Inhibitors; F	2019
Monotherapy with a P2Y Lancet (London, England), 2020, 05-09, Volume: 395, Issue:10235 Topics: Aged; Aspirin; Atherosclerosis; Cerebrovascular Disorders; Clopidogrel; Coronary Disease; Female; He	2020
Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence. Thrombosis and haemostasis, 2020, Volume: 120, Issue:8 Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atherosclerosis; Dose-Response Relationship, Drug;	2020
[Do the patients with peripheral atherosclerosis need to a medical therapy before the revascularization?] Terapevticheskii arkhiv, 2019, Dec-15, Volume: 91, Issue:12 Topics: Aspirin; Atherosclerosis; Drug Therapy, Combination; Humans; Peripheral Arterial Disease; Rivaroxaba	2019
Aspirin and low-dose rivaroxaban - the dual pathway concept in patients with stable atherosclerotic disease: a comprehensive review. Expert review of cardiovascular therapy, 2020, Volume: 18, Issue:9 Topics: Aspirin; Atherosclerosis; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Humans; Perip	2020
Efficacy and Safety of Antiplatelet Therapies in Symptomatic Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis. Current vascular pharmacology, 2021, Volume: 19, Issue:5 Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Network Meta-Analysis; Peripheral Arterial	2021
The efficacy and safety of direct oral anticoagulants plus aspirin in symptomatic lower extremity peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials. Journal of thrombosis and thrombolysis, 2021, Volume: 52, Issue:3 Topics: Anticoagulants; Aspirin; Factor Xa Inhibitors; Hemorrhage; Humans; Ischemia; Lower Extremity; Periph	2021
Clinical considerations after endovascular therapy of peripheral artery disease. Expert review of cardiovascular therapy, 2021, Volume: 19, Issue:5 Topics: Antihypertensive Agents; Aspirin; Endovascular Procedures; Humans; Hydroxymethylglutaryl-CoA Reducta	2021
Contemporary Medical Management of Peripheral Artery Disease. Circulation research, 2021, 06-11, Volume: 128, Issue:12 Topics: Aspirin; Atherosclerosis; Cardiovascular Diseases; Chronic Limb-Threatening Ischemia; Exercise; Fibr	2021
Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation. International journal of molecular sciences, 2021, Jul-01, Volume: 22, Issue:13 Topics: Anticoagulants; Aspirin; Blood Coagulation; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrino	2021
Network Meta-analysis of the Benefit of Aspirin with Rivaroxaban vs. Clopidogrel for Patients with Stable Symptomatic Lower Extremity Arterial Disease. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2021, Volume: 62, Issue:4 Topics: Aged; Aspirin; Clopidogrel; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; L	2021
Pharmacological secondary prevention in patients with mesenterial artery atherosclerosis and arterial embolism. Best practice & research. Clinical gastroenterology, 2017, Volume: 31, Issue:1 Topics: Anticoagulants; Aspirin; Atherosclerosis; Embolism; Humans; Peripheral Arterial Disease; Secondary P	2017
Review of aspirin and clopidogrel resistance in peripheral arterial disease. Journal of vascular surgery, 2017, Volume: 66, Issue:5 Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Resistance; Genotype; Humans; Peripheral Arteri	2017
Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease. Critical pathways in cardiology, 2018, Volume: 17, Issue:2 Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; DNA; Drug Therapy, Combination; Facto	2018
A systematic review of the efficacy of aspirin monotherapy versus other antiplatelet therapy regimens in peripheral arterial disease. Journal of vascular surgery, 2018, Volume: 67, Issue:6 Topics: Aspirin; Endovascular Procedures; Fibrinolytic Agents; Humans; Peripheral Arterial Disease; Platelet	2018
Screening for Peripheral Artery Disease Using the Ankle-Brachial Index: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA, 2018, 07-10, Volume: 320, Issue:2 Topics: Ankle Brachial Index; Aspirin; Asymptomatic Diseases; Early Diagnosis; Exercise Therapy; Fibrinolyti	2018
Dual vs single antiplatelet therapy in patients with lower extremity peripheral artery disease - A meta-analysis. International journal of cardiology, 2018, Oct-15, Volume: 269 Topics: Aspirin; Drug Therapy, Combination; Humans; Lower Extremity; Peripheral Arterial Disease; Platelet A	2018
[Anti-Thrombotic Treatment of Patients with Peripheral Artery Disease (PAD)]. Deutsche medizinische Wochenschrift (1946), 2018, Volume: 143, Issue:15 Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Dr	2018
Novel Oral Anticoagulants in Peripheral Artery Disease: Current Evidence. Current pharmaceutical design, 2018, Volume: 24, Issue:38 Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Hemorrhage; Humans;	2018
Rivaroxaban versus Clopidogrel for Peripheral Artery Disease: A Clinico-Economic Approach of the COMPASS Trial. Current pharmaceutical design, 2018, Volume: 24, Issue:38 Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Clopidogrel; Cost-Benefit Analysis; Drug Therapy,	2018
Antithrombotic Agents. Circulation research, 2019, Volume: 124, Issue:3 Topics: Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clinical Trials a	2019
Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease. Circulation, 2019, 04-30, Volume: 139, Issue:18 Topics: Administration, Oral; Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Disease; Humans; Percuta	2019
How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland? Kardiologia polska, 2019, Aug-23, Volume: 77, Issue:7-8 Topics: Aged; Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Hum	2019
Is aspirin still the drug of choice for management of patients with peripheral arterial disease? VASA. Zeitschrift fur Gefasskrankheiten, 2013, Volume: 42, Issue:2 Topics: Aspirin; Cardiovascular Diseases; Disease Progression; Fibrinolytic Agents; Humans; Peripheral Arter	2013
High on-treatment platelet reactivity in peripheral endovascular procedures. Cardiovascular and interventional radiology, 2014, Volume: 37, Issue:3 Topics: Aspirin; Atherosclerosis; Blood Platelets; Clopidogrel; Endovascular Procedures; Humans; Peripheral	2014
Management of patients after endovascular interventions for peripheral artery disease. Circulation, 2013, Aug-13, Volume: 128, Issue:7 Topics: Aftercare; Angioplasty, Balloon; Ankle Brachial Index; Aspirin; Cilostazol; Clinical Trials as Topic	2013
The ankle-brachial index for peripheral artery disease screening and cardiovascular disease prediction among asymptomatic adults: a systematic evidence review for the U.S. Preventive Services Task Force. Annals of internal medicine, 2013, Sep-03, Volume: 159, Issue:5 Topics: Adult; Ankle Brachial Index; Aspirin; Asymptomatic Diseases; Cardiovascular Diseases; Fibrinolytic A	2013
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. Annals of medicine, 2014, Volume: 46, Issue:7 Topics: Adenosine; Aspirin; Asymptomatic Diseases; Cilostazol; Clopidogrel; Fibrinolytic Agents; Humans; Int	2014
Antiplatelet therapy for peripheral arterial disease and critical limb ischemia: guidelines abound, but where are the data? Journal of cardiovascular pharmacology and therapeutics, 2015, Volume: 20, Issue:2 Topics: Aspirin; Cilostazol; Dipyridamole; Endovascular Procedures; Extremities; Humans; Ischemia; Periphera	2015
Comparative effectiveness review of antiplatelet agents in peripheral artery disease. Journal of the American Heart Association, 2014, Dec-04, Volume: 3, Issue:6 Topics: Aspirin; Clopidogrel; Comparative Effectiveness Research; Drug Therapy, Combination; Humans; Patient	2014
The year in cardiology 2014: peripheral circulation. European heart journal, 2015, Mar-07, Volume: 36, Issue:10 Topics: Anticoagulants; Aortic Aneurysm, Abdominal; Aspirin; Biomarkers; Carotid Artery Diseases; Endovascul	2015
A Meta-Analysis of Randomized Controlled Trials on Antiplatelet Agents Versus Placebo/Control for Treating Peripheral Artery Disease. Medicine, 2015, Volume: 94, Issue:31 Topics: Aspirin; Humans; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Randomized Controlled	2015
Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2015, Oct-01, Volume: 72, Issue:19 Topics: Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Half-Life; Hemorrhage; Humans; L	2015
Antithrombotic Therapy After Peripheral Vascular Intervention. Current cardiology reports, 2016, Volume: 18, Issue:3 Topics: Angioplasty, Balloon; Aspirin; Atherectomy; Fibrinolytic Agents; Humans; Peripheral Arterial Disease	2016
Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation. Thrombosis and haemostasis, 2016, 05-02, Volume: 115, Issue:5 Topics: Animals; Aspirin; Clopidogrel; Diplopia; Drug Approval; Eye; Humans; Lactones; Peripheral Arterial D	2016
[The basis of platelets: platelets and atherothrombosis: an understanding of the lack of efficacy of aspirin in peripheral arterial disease (PAD) and diabetic patients]. Drugs, 2010, Nov-01, Volume: 70 Suppl 1 Topics: Abbreviations as Topic; Aspirin; Atherosclerosis; Blood Platelets; Clinical Trials as Topic; Diabete	2010
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. Health technology assessment (Winchester, England), 2011, Volume: 15, Issue:31 Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Clopidogrel; Cost-Benefit Analysis; Delayed-Ac	2011
Antiplatelet therapy in peripheral artery disease. Handbook of experimental pharmacology, 2012, Issue:210 Topics: Ankle Brachial Index; Arachidonic Acid; Aspirin; Humans; Peripheral Arterial Disease; Platelet Aggre	2012
[Antithrombotic therapy after peripheral vascular treatment: what is evidence-based?]. Zentralblatt fur Chirurgie, 2012, Volume: 137, Issue:5 Topics: Aortic Diseases; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Dose-Response Relations	2012

aspirin and Peripheral Arterial Diseases